CLL is a malignant disease characterized by progressive accumulation of immature, immunophenotypically distinct lymphocytes in the blood, bone marrow, and lymphatic tissues. Although the clinical course of CLL can be unpredictable, this disease is typically slow-progressing and occurs most often in....
..when researchers treated #AML patients with #Venetoclax #leukaemia stem cells died... without harming healthy cells [But] it was only patients who were treated with Venetoclax as the 1st treatment that showed such a dramatic response.
"When patients were treated with other therapies first, leukemia stem cells were pushed to diversify and some adopted lipid metabolism," Jones says. When those patients were subsequently treated with venetoclax, the drug killed the cancer stem cells that continued to depend on amino acid metabolism, but was ineffective against cancer stem cells that had switched to lipid metabolism. It was as if lipid metabolism provided an avenue of escape for these cells, and when even a small population of leukemia stem cells was able to resist therapy, they were able to later restart the growth of the disease. | via ScienceDaily ow.ly/55E930mC9Xb... See MoreSee Less
A new study shows that cancer stem cells switch from metabolizing sugar to metabolizing protein. Clinical trial based on this observation may revolutionize care for older adults with acute myeloid leukemia.
Dublin: Clinical Research Education Day Wed, Dec 5, 2018 at 5:00 PM Free educational forum will provide information about the clinical research process and activity here in Dublin, as well as food, prizes, and free health screenings. Register on Eventbrite ow.ly/2ArN30mBJ05... See MoreSee Less
AWARE for All - Dublin: Clinical Research Education Day is a free educational event that serves as a forum for open dialogue between patients, members of the public, and health and research professionals. AWARE for All will provide information about the clinical research process and activity here in...
Have you seen CLL Ireland's videos on our website yet? The excellent presentation given by Louise O'Driscoll, Senior Clinical Psychologist in SVUH to our community at our recent 'Stormy Minds Can be Calmed' event in Mullingar features. clli.ie/news-and-events/videos/... See MoreSee Less
"The word cure can now be used in oncology,” says Dr Axel Hoos, an immunologist and former global medical lead for the Bristol-Myers Squibb immune-oncology programme. “It’s no longer fantasy or a cruel promise that you can’t fulfil...." ow.ly/9uLF30mzyKi... See MoreSee Less
Louise O Driscoll, Senior Clinical Psychologist St. Vincent's Hospital, Dublin recently gave an excellent presentation, and very generously of her time, at our recent evening of psychological support for #CLL patients and their families. For those who were unable to join us it's well worth a watch: t.co/SIWIVV1VhULouise O'Driscoll, Clinical Psychologist, St. Vincent's Hospital Dublin discusses how CLL patients can help deal with the psychological impact of their blood... ... See MoreSee Less
Therapy combines an experimental antibody [Hu5F9-G4] developed by researchers at Stanford Medicine & a commercially available anti-cancer antibody called rituximab. 50% of those on the trial had a positive response to and 1/3rd went into complete remission. ow.ly/gI0a30mxEYs... See MoreSee Less
A novel immunotherapy appears safe for use in patients with a type of blood cancer called non-Hodgkin's lymphoma, according to a phase-1 multicenter clinical trial led by a researcher at the Stanford University School of Medicine.
Basel, 1 November 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with MabThera® (rituximab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior ...
#Ibrutinib Gazyva Combo for #CLL /SLL Granted FDA Priority Review If approved, this will be the first chemotherapy-free combination containing a CD20 antibody approved for the first-line treatment of CLL/SLL | via Lymphoma News Today